Jatana Kris R, Balasubramanian Priya, Lang Jas C, Yang Liying, Jatana Courtney A, White Elisabeth, Agrawal Amit, Ozer Enver, Schuller David E, Teknos Theodoros N, Chalmers Jeffrey J
Department of Otolaryngology-Head and Neck Surgery, The Ohio State University and Nationwide Children's Hospital, 555 S 18th St, Columbus, OH 43205, USA.
Arch Otolaryngol Head Neck Surg. 2010 Dec;136(12):1274-9. doi: 10.1001/archoto.2010.223.
to present and discuss a high-performance negative depletion method for the isolation of circulating tumor cells (CTCs) in the blood of patients with head and neck cancer and to determine the correlation between the presence of CTCs and early clinical outcome in these patients.
prospective clinical follow-up study of patients with squamous cell carcinoma of the head and neck (SCCHN) undergoing surgical intervention, who had peripheral blood examined for the presence of CTCs.
the study population comprised 48 patients diagnosed as having SCCHN and undergoing surgical intervention.
a negative depletion process to isolate and quantify CTCs from the blood of patients with SCCHN using immunomagnetic separation was developed and validated. Immunostaining for cytokeratin was performed on the enriched samples to determine the number of CTCs extracted from each patient's blood sample. Correlation of the presence of CTCs, tumor stage, nodal status, clinical characteristics, and outcome was made.
disease-free survival.
our initial data, that have a mean follow-up of 19.0 months, suggest that patients with no detectable CTCs per milliliter of blood had a significantly higher probability of disease-free survival (P = .01). There was no correlation between the presence of CTCs with regard to age, sex, tumor site, stage, or nodal involvement.
our enrichment technology, based on the removal of normal cells, has been used on the peripheral blood of patients with head and neck cancer for which follow-up data were collected. If no CTCs were present, a statistically significant improved disease-free survival was observed in SCCHN. A blood test with such a prognostic capability could have important implications in the treatment of patients with head and neck cancer.
介绍并讨论一种用于分离头颈部癌患者血液中循环肿瘤细胞（CTC）的高效阴性去除法，并确定这些患者中CTC的存在与早期临床结局之间的相关性。
对头颈部鳞状细胞癌（SCCHN）患者进行手术干预，并对其外周血进行CTC检测的前瞻性临床随访研究。
研究人群包括48例被诊断为SCCHN并接受手术干预的患者。
开发并验证了一种使用免疫磁珠分离法从SCCHN患者血液中分离和定量CTC的阴性去除法。对富集后的样本进行细胞角蛋白免疫染色，以确定从每位患者血样中提取的CTC数量。分析了CTC的存在与肿瘤分期、淋巴结状态及临床特征和结局之间的相关性。
无病生存期。
我们的初始数据平均随访时间为19.0个月，结果显示每毫升血液中未检测到CTC的患者无病生存概率显著更高（P = 0.01）。CTC的存在与年龄、性别、肿瘤部位、分期或淋巴结受累情况之间无相关性。
我们基于去除正常细胞的富集技术已应用于收集了随访数据的头颈部癌患者的外周血。在SCCHN中，如果不存在CTC，则观察到无病生存期有统计学意义的显著改善。具有这种预后能力的血液检测对头颈部癌患者的治疗可能具有重要意义。
